The needle on an insulin syringe is tiny
It belongs to a group of medicines known as GLP-1 receptor agonists
no clear plateau) Zepbound: ~20% to 22.5% (long-term studies) Glycemic Control (T2D): Retatrutide: HbA1c reduction up to ~2.0% (Phase III) Zepbound: Strong, well-established HbA1c reductions (~2.0% to 2.4%) across Phase III trials Durability of Effect: Retatrutide: Sustained weight loss with continued decline over time Zepbound: Durable, but tends to plateau earlier Safety & Tolerability: Retatrutide: Higher rates of GI side effects
other GLP-1 drugs: Side effect comparison Retatrutide has a similar side effect profile to other popular weight loss medications, such as semaglutide (Wegovy/Ozempic) and tirzepatide (Mounjaro/Zepbound)
Semaglutide, the active ingredient in Ozempic and Wegovy, activates only the GLP-1 receptor
Research Rationale BPC-157 upregulates angiogenic growth factors (VEGF, TGF-) to build vascular infrastructure TB-500 provides the actin-binding platform for cell migration into the repair site BPC-157 modulates nitric oxide synthesis and protects endothelial integrity, while TB-500 regulates inflammatory signalling and reduces oxidative stress The two peptides target separate phases of tissue repair: BPC-157 drives early-stage angiogenesis and granulation, TB-500 supports later-stage matrix remodelling Each compound is individually vialled and batch-traceable with independent COAs stack at your chosen concentrations Research Applications This stack is used in laboratory models of soft tissue repair, wound healing assays, endothelial cell migration studies, and inflammation-modulation research
